Compare Charles River Laboratories Intl. Inc (CRL) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Teladoc Health Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 14.1× Teladoc Health Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Teladoc Health Inc for 39 Days on average.
| CRL | TDOC | |
|---|---|---|
Market Cap | $14.23B | $1.01B |
Volume | 1,176,885 | 4,668,477 |
Sector | Health | Health |
52-Week High | $310.77 | $9.72 |
52-Week Low | $149.93 | $4.47 |
Typical Hold Time | 33 Days | 39 Days |
Enterprise Value | $17.06B | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
